A common ovarian cancer evades detection by convincing nearby immune cells to treat it as a developing fetus.
Pioneering immunotherapy drug Provenge is enjoying a revival, thanks to a large new clinical trial that will test it in men with early prostate cancer.
Stanford scientists have moved a big step closer toward using engineered immune cells to treat many forms of pediatric cancer.
A novel immunotherapy appears safe for use in patients with non-Hodgkin’s lymphoma. Here, a Northern California man shares his experience in the study.